Can I Take Resveratrol with Sildenafil (Generic)?

What Resveratrol Actually Does in the Body

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in grape skins, red wine, and Japanese knotweed. Oral bioavailability of unformulated resveratrol sits below 1% after first-pass metabolism, yet peak plasma concentrations after a 500 mg dose can reach 2 to 3 µmol/L, which is sufficient to inhibit several drug-metabolizing enzymes in vitro and, to a meaningful degree, in vivo. [1]

Metabolism and Enzyme Inhibition

Resveratrol is metabolized mainly by sulfation and glucuronidation, but it inhibits CYP1A2, CYP2C9, CYP2D6, and CYP3A4 at concentrations achievable with standard supplement doses. [2] A 2010 pharmacokinetic study published in Drug Metabolism and Disposition found that resveratrol (1 g orally for four days) reduced CYP3A4 activity by roughly 50% and CYP2D6 by 51% in healthy volunteers. [3] That is not a trivial inhibition percentage for a supplement most people assume is harmless.

Estrogenic Activity

Resveratrol binds estrogen receptors ERα and ERβ, acting as a selective estrogen receptor modulator (SERM). [4] In men, high-dose resveratrol could theoretically affect testosterone-to-estrogen balance, though clinical evidence at OTC doses (150 to 500 mg) is limited. The FDA has not evaluated resveratrol's hormonal effects for any approved indication. [5]

How Sildenafil Is Metabolized and Why That Matters

Sildenafil is cleared primarily by CYP3A4 (major pathway) and CYP2C9 (minor pathway) in the liver. [6] Its mean terminal half-life is approximately 4 hours at therapeutic doses of 25 to 100 mg. When CYP3A4 is inhibited, sildenafil clearance slows, plasma concentrations rise, and both the therapeutic effect and adverse-effect profile intensify.

The PDE5 Mechanism

Sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic GMP in vascular smooth muscle. This produces vasodilation. [6] Nitric oxide-mediated vasodilation is also the mechanism behind many of sildenafil's adverse effects: headache, flushing, and hypotension. Any co-administered substance that raises sildenafil plasma levels will amplify those same effects.

Known CYP3A4 Inhibitors and Sildenafil

The FDA label for sildenafil explicitly warns that potent CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin) can increase sildenafil AUC by 2- to 11-fold. [6] Resveratrol is a moderate, not potent, CYP3A4 inhibitor, so the magnitude of sildenafil AUC increase is smaller, estimated at 20 to 50% based on the enzyme-inhibition data, but it is not zero. [3]

The Direct Interaction: Pharmacokinetic and Pharmacodynamic

CYP3A4/2C9 Inhibition Raises Sildenafil Exposure

When resveratrol slows CYP3A4 and CYP2C9, sildenafil is cleared more slowly. The result is a longer time above therapeutic plasma concentrations. For a man taking sildenafil 100 mg, already the ceiling recommended dose, even a 25 to 30% rise in AUC moves the drug into territory the prescriber did not intend. [6] Blood pressure can drop more than expected, and effects such as flushing and headache last longer.

A 2022 review in Nutrients examining polyphenol-drug interactions catalogued resveratrol as one of the more clinically relevant CYP3A4 inhibitors among commonly used plant-derived supplements, particularly at doses above 500 mg/day. [7]

Additive Vasodilation

Both compounds lower blood pressure through nitric oxide-related pathways. Resveratrol activates endothelial nitric oxide synthase (eNOS) independently. [8] Sildenafil amplifies the downstream cGMP signal. Taking both together creates at least an additive, and possibly a synergistic, vasodilatory signal. For men with baseline hypotension or those on antihypertensive therapy, this combination may produce symptomatic drops in blood pressure (dizziness, near-syncope). [9]

Is This Interaction Pharmacokinetic or Pharmacodynamic?

It is both. The pharmacokinetic component (CYP inhibition raising sildenafil levels) is the larger concern at typical supplement doses. The pharmacodynamic component (additive vasodilation via eNOS and PDE5) adds a second, independent layer of risk. [3][8]

What the Clinical Literature Actually Shows

No randomized controlled trial has studied the resveratrol, sildenafil combination directly in humans. That absence of data is itself clinically informative: absence of evidence is not evidence of absence of harm.

Resveratrol's Cardiovascular Effects at Tested Doses

A 2011 Lancet Oncology investigation (N=38 patients, colorectal cancer cohort) found that resveratrol 0.5 to 1 g/day produced measurable reductions in IGF-1. [10] Separately, a 2018 meta-analysis in the American Journal of Clinical Nutrition (18 RCTs, N=1,209) reported that resveratrol supplementation significantly reduced systolic blood pressure by a mean of 2.0 mmHg and diastolic by 1.5 mmHg (P<0.05) compared to placebo. [11] A 2 mmHg systolic reduction may appear small in isolation, but added to sildenafil's blood-pressure-lowering effect, which can reach 8 to 10 mmHg in normotensive men at 100 mg, the combined drop becomes clinically relevant. [6]

CYP Inhibition: The Most Cited Human Data

The most directly applicable human pharmacokinetic data comes from a study by Chow et al. (2010, Drug Metabolism and Disposition), in which 500 mg and 1,000 mg resveratrol doses given over four days measurably inhibited CYP3A4 activity in healthy adults, with the 1,000 mg dose producing approximately 50% inhibition. [3] Standard supplement products sold in 500 mg capsules sit right at the threshold where CYP3A4 inhibition begins to be clinically detectable.

Estrogenic Effects: Limited Human Data

Resveratrol's SERM activity has been studied primarily in postmenopausal women and in vitro models. [4] For men using sildenafil for erectile dysfunction, the estrogenic concern is secondary, but worth knowing if resveratrol is taken long-term at doses above 500 mg/day, where effects on sex-hormone-binding globulin and estradiol may theoretically reduce the androgenic environment needed for optimal sexual function. [12]

Dose-Specific Risk Profile

Sildenafil 20 mg (Pulmonary Hypertension or Low ED Dose)

At 20 mg, even a 30 to 40% AUC increase from CYP3A4 inhibition is unlikely to produce clinically meaningful hypotension in most men. Risk is low.

Sildenafil 50 mg (Standard Starting Dose)

The 50 mg dose is where CYP3A4 inhibition becomes more clinically noticeable. A 30% AUC increase effectively converts a 50 mg dose into the pharmacokinetic equivalent of 65 mg. Flushing, prolonged headache, and mild hypotension are plausible.

Sildenafil 100 mg (Maximum Recommended Dose)

At 100 mg, the prescriber has already reached the FDA-approved ceiling. Any further increase in plasma exposure from CYP3A4 inhibition, even moderate, should be avoided. Men on 100 mg sildenafil should disclose resveratrol use to their physician before continuing. [6]

Resveratrol Dose Thresholds

• Below 150 mg/day: CYP3A4 inhibition is minimal; interaction risk is probably negligible.
• 150 to 500 mg/day: Mild CYP3A4 inhibition; interaction risk is low to moderate. [3]
• Above 500 mg/day: Moderate CYP3A4 inhibition is measurable in human studies; interaction risk is moderate. [3]

Can You Separate the Doses to Avoid the Interaction?

This question comes up often. The short answer: dose separation does not reliably solve a CYP inhibition problem. CYP3A4 inhibition by resveratrol is not acute (occurring only at the moment of co-ingestion). It builds up over days of supplementation and persists until resveratrol and its active metabolites are cleared, a process that takes 24 to 48 hours after the last dose. [3] Spacing sildenafil and resveratrol by several hours on the same day does not meaningfully reduce the interaction.

If you want to use resveratrol only occasionally (once per week or less), the CYP inhibition has less time to accumulate. That pattern is lower risk, though still not studied in direct combination with sildenafil.

Monitoring: What to Watch For

Men taking both compounds should watch for these signs that sildenafil exposure may be elevated:

• Flushing or facial redness lasting more than 4 to 5 hours after taking sildenafil
• Headache that is more severe or prolonged than usual
• Dizziness or lightheadedness, especially on standing
• Visual disturbance (blue-tinged vision or light sensitivity) lasting beyond 6 hours
• Erection lasting more than 4 hours (priapism), this is a medical emergency requiring immediate care [6]

Blood pressure monitoring at home (using a validated cuff) is reasonable for any man combining sildenafil with vasodilatory supplements. The American Heart Association recommends home blood pressure monitoring for men with hypertension who are adjusting medications or adding supplements that affect vascular tone. [9]

What to Tell Your Prescriber

Disclosure is the most important single step. Bring the following information to your next appointment or telehealth visit:

1. The brand and dose of resveratrol you are taking (mg per capsule, frequency).
2. The dose of sildenafil prescribed (20 mg, 50 mg, or 100 mg) and how often you use it.
3. Any other supplements or medications you take that could affect CYP3A4 (grapefruit juice, St. John's Wort, ketoconazole, fluconazole). [13]
4. Your resting blood pressure and any history of hypotension.

Your prescriber may decide to keep both at their current doses with monitoring, reduce sildenafil to the next lower dose as a precaution, or recommend stopping resveratrol if you are on 100 mg sildenafil and already have borderline blood pressure.

Drug-Supplement Interaction Databases: What They Say

The Natural Medicines database (formerly Natural Standard) rates the resveratrol, sildenafil combination as a "moderate" interaction, citing CYP3A4 inhibition as the primary mechanism. [14] Drugs.com lists this as a potential interaction requiring monitoring. The FDA has not issued a specific warning about this combination, as resveratrol is regulated as a dietary supplement, not a drug, and interaction testing with sildenafil has not been required by any regulatory authority. [5]

Comparing Resveratrol to Other Common Sildenafil Interactions

For perspective, grapefruit juice increases sildenafil AUC by approximately 23% via intestinal CYP3A4 inhibition. [6] Ketoconazole (200 mg) increases sildenafil AUC by roughly 200%. [6] Resveratrol at 500 mg sits closer to grapefruit juice than to ketoconazole on the risk spectrum. The FDA already recommends avoiding grapefruit with sildenafil, which suggests a similar precautionary posture toward other moderate CYP3A4 inhibitors including resveratrol is warranted. [6]

Special Populations: Who Faces Higher Risk

Men Over 65

Older adults have reduced hepatic CYP3A4 activity at baseline. [15] The FDA already recommends starting sildenafil at 25 mg in men over 65. Adding a moderate CYP3A4 inhibitor on top of an already-reduced clearance capacity compounds the risk of elevated sildenafil exposure. Men over 65 should be especially conservative about adding resveratrol supplementation. [6]

Men with Cardiovascular Disease

Resveratrol has been studied in post-infarction and heart failure populations. A 2016 systematic review in the Journal of Cardiovascular Pharmacology (12 RCTs) found resveratrol produced modest improvements in flow-mediated dilation but also reduced blood pressure, which interacts additively with sildenafil's vasodilatory profile. [16] Men already on antihypertensives plus sildenafil face the highest combined vasodilatory burden.

Men with Liver Disease

CYP3A4 is predominantly hepatic. Any degree of hepatic impairment reduces sildenafil clearance. Adding a CYP3A4 inhibitor in a patient with hepatic impairment stacks two separate clearance-reduction mechanisms. The FDA label for sildenafil notes that AUC increases approximately 84% in patients with hepatic cirrhosis. [6]

Resveratrol's Longevity Claims vs. Its Actual Evidence Base

Many men add resveratrol to their stack based on sirtuin-activation and longevity claims. The SIRT1 activation hypothesis was largely derived from David Sinclair's laboratory work at Harvard, beginning with a landmark 2003 Nature paper showing resveratrol activated yeast Sir2 (a SIRT1 homolog). [17] However, a 2010 paper in Journal of Biological Chemistry found that the fluorescent assay used in those early studies was a technical artifact; direct SIRT1 activation by resveratrol was not reproducible without the fluorescent peptide substrate. [18]

Clinical trials in humans have not confirmed the longevity benefits. What the trials have shown: modest anti-inflammatory effects, modest blood-pressure reduction, and CYP enzyme inhibition. [11] For a man taking sildenafil, the blood-pressure and CYP effects are the clinically relevant findings.

Practical Guidance If You Are Already Taking Both

If you are currently taking resveratrol and sildenafil together without obvious adverse effects, you do not need to panic. The interaction is low-to-moderate risk, not contraindicated. Do these four things:

1. Tell your prescriber at your next visit (or send a message through your patient portal today).
2. Check your resting blood pressure at home before and 1 to 2 hours after taking sildenafil.
3. Note whether headache, flushing, or dizziness after sildenafil seems more pronounced than it was before you added resveratrol.
4. Avoid increasing your resveratrol dose above 500 mg/day without medical input.

The Endocrine Society's position on supplement-drug interactions in men's health states: "Clinicians should routinely inquire about dietary supplement use, as many supplements exert pharmacologically relevant effects on drug-metabolizing enzymes." [19]